Merck Research Labs' antibody effort blasts off

Merck ($MRK) has gone to the ends of the earth to develop new antibodies. Now it's headed into space. Merck Research Laboratories is turning to the International Space Station to see whether a microgravity environment can help it better study antibodies. Investigators have gone into space before to use the environment to gain higher resolution of antibody structures in the complex engineering work they do. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.